| No. of survivors | No. of non-survivors | OR (95% CI) | p |
---|---|---|---|---|
(n = 456) | (n = 97) | |||
Age (year) (mean ±SD) | 61.1 (±13.5) | 63.3 (±12.1) |  | 0.146 |
Male sex | 287 (62.9) | 61 (62.9) | 1.00 (0.63-1.57) | 0.992 |
Underlying disease | Â | Â | Â | Â |
  Diabetes mellitus | 128 (28.1) | 17 (17.5) | 0.55 (0.31-0.96) | 0.032 |
  Chronic liver disease | 94 (20.6) | 29 (29.9) | 1.64 (1.01-2.68) | 0.046 |
  Biliary tract disease | 77 (16.9) | 8 (8.2) | 0.44 (0.21-0.95) | 0.032 |
  Chronic kidney disease | 28 (6.1) | 4 (4.1) | 0.66 (0.26-1.92) | 0.440 |
  Respiratory disease | 34 (7.5) | 5 (5.2) | 0.68 (0.26-1.77) | 0.421 |
  Solid tumor | 173 (37.9) | 65 (67.0) | 3.32 (2.09-5.28) | <0.001 |
  Hematologic malignancy | 16 (3.5) | 11 (11.3) | 3.52 (1.58-7.84) | 0.003 |
  Solid organ transplantation | 13 (2.9) | 1 (1.0) | 0.36 (0.05-2.75) | 0.482 |
Charlson's WIC (≥3) | 135 (29.6) | 53 (54.6) | 2.86 (1.83-4.48) | <0.001 |
Primary infection site | Â | Â | Â | Â |
  Urinary tract | 58 (12.7) | 7 (7.2) | 0.53 (0.24-1.22) | 0.126 |
  Peritoneum | 42 (9.2) | 15 (15.5) | 1.80 (0.96-3.40) | 0.066 |
  Pancreatobiliary tract | 163 (35.7) | 21 (21.6) | 0.50 (0.30-0.84) | 0.007 |
  Liver | 105 (23.0) | 3 (3.1) | 0.11 (0.03-0.35) | <0.001 |
  Lung | 27 (5.9) | 17 (17.5) | 3.38 (1.76-6.48) | <0.001 |
  Skin and soft tissue | 8 (1.8) | 4 (4.1) | 2.41 (0.71-8.17) | 0.239 |
  Bone | 5 (1.1) | 1 (1.0) | 0.94 (0.11-8.13) | 1.000 |
  Central nervous system | 1 (0.2) | 0 (0) | 0.82 (0.79-0.86) | 1.000 |
  Othersa | 3 (0.7) | 1 (1.0) | 1.57 (0.16-15.28) | 0.539 |
  Unknown | 45 (9.9) | 28 (28.9) | 3.71 (2.17-6.34) | <0.001 |
Metastatic infection | 18 (3.9) | 2 (2.1) | 0.51 (0.12-2.25) | 0.551 |
Endophthalmitis | 8 (1.8) | 0 (0) | 0.82 (0.79-0.86) | 0.362 |
Pitt bacteremia score (≥4) | 46 (10.1) | 46 (47.4) | 8.04 (4.87-13.28) | <0.001 |
Shock at presentation | 97 (21.3) | 59 (60.8) | 5.75 (3.61-9.15) | <0.001 |
Neutropenia at presentation | 25 (5.5) | 20 (20.6) | 4.48 (2.37-8.46) | <0.001 |
Healthcare-associated infection | 243 (53.3) | 70 (72.2) | 2.27 (1.41-3.68) | 0.001 |
Polymicrobial infection | 57 (12.5) | 24 (24.7) | 2.30 (1.34-3.94) | 0.002 |
Antimicrobial resistance | Â | Â | Â | Â |
  non-susceptible to CIP | 32 (7.0) | 9 (9.3) | 1.36 (0.63-2.94) | 0.440 |
  non-susceptible to ESC | 29 (6.4) | 8 (8.2) | 1.32 (0.59-2.99) | 0.499 |
Inappropriate empirical antimicrobial therapy | 27 (5.9) | 13 (13.4) | 2.46 (1.22-4.96) | 0.010 |
Inappropriate definitive antimicrobial therapyb | 12/446 (2.7) | 2/55 (3.6) | 1.37 (0.30-6.26) | 0.659 |